Biomaterial Database

A comparative trial of co-trimoxazole and chloramphenicol in thyphoid and paratyphoid fever. 1978

S Ramachandran, and J J Godfrey, and N D Lionel

A comparative trial of co-trimoxazole and chloramphenicol was carried out on 91 patients, 57 having typhoid fever and 34 cases having paratyphoid fever. Co-trimoxazole is an effective drug in the treatment of enteric fevers with respect to clinical cure, absence of relapses and the mild nature of short term toxic drug effects. Unlike some of the earlier reports, treatment failure or non-responsiveness to the drug occurred in just under 10 per cent of the cases and would constitute a drawback of therapy with co-trimoxazole. This feature was not observed in the patients receiving chloramphenicol. The excretion of Salmonellae after drug therapy was more common with chloramphenicol than with co-trimoxazole, again indicating the value of the latter drug in the treatment of enteric fevers.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D010284	Paratyphoid Fever	A prolonged febrile illness commonly caused by several Paratyphi serotypes of SALMONELLA ENTERICA. It is similar to TYPHOID FEVER but less severe.	Fever, Paratyphoid,Fevers, Paratyphoid,Paratyphoid Fevers
D002701	Chloramphenicol	An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106)	Cloranfenicol,Kloramfenikol,Levomycetin,Amphenicol,Amphenicols,Chlornitromycin,Chlorocid,Chloromycetin,Detreomycin,Ophthochlor,Syntomycin
D002986	Clinical Trials as Topic	Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.	Clinical Trial as Topic
D004338	Drug Combinations	Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.	Drug Combination,Combination, Drug,Combinations, Drug
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D013420	Sulfamethoxazole	A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208)	Sulfamethylisoxazole,Gantanol,Sulfisomezole,Sulphamethoxazole
D014295	Trimethoprim	A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.	Proloprim,Trimpex